Evidence map›Paper›PMID 41882227›Full record

ArticleThe EMBO journal2026

GTPase Rab11b and effector Rab11-FIP2 promote NLRP3 stability during inflammasome priming.

Caroline S Gravastrand, Maria Yurchenko, Stine Kristensen, Astrid Skjesol, Carmen Chen, Sindre Ullmann, Zunaira Iqbal, Karoline Ruud Dahlen, Kashif Rasheed, Unni Nonstad and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Caroline S GravastrandCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Maria YurchenkoCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Stine KristensenCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Astrid SkjesolCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Carmen ChenCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.ORCID http://orcid.org/0009-0004-8304-5825
Sindre UllmannCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Zunaira IqbalCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.ORCID http://orcid.org/0000-0001-6329-6345
Karoline Ruud DahlenCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Kashif RasheedCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.ORCID http://orcid.org/0000-0002-8945-5559
Unni NonstadCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Liv RyanCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Terje EspevikCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Harald HusebyeCentre of Molecular Inflammation Research, Department of Clinical Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. harald.husebye@ntnu.no.ORCID http://orcid.org/0000-0002-8828-1059

Funding

Norges Forskningsråd (Forskningsrådet) 100412100Norges Forskningsråd (Forskningsrådet) 223255/F50Norges Forskningsråd (Forskningsrådet) 275876The Research Council of Norway, FRIPRO 334787
6 · The paper itself

Abstract

Membrane trafficking through the trans-Golgi network has been shown to guide activation of the NLRP3 inflammasome. Rab11 GTPases and their effector Rab11-FIP2 regulate endosomal trafficking and retrograde transport. Here, we demonstrate that Rab11b and Rab11-FIP2 contribute to NLRP3 and pro-IL-1β stabilization during the inflammasome priming phase, which is followed by inflammasome activation. We show Rab11-FIP2 to promote TAK1 phosphorylation and TAK1-mediated activation of IKKβ, a process controlling NLRP3 translocation to the trans-Golgi network. Human NLRP3 and Rab11-FIP2 bind each other via their phosphatidylinositol-4 phosphate (PI4P)-binding domains KMKK and N-terminal C2 domain, respectively. We also provide evidence indicating that Rab11-FIP2 stabilizes NLRP3 on early endosomes, which is important for ASC speck formation. These findings provide insights into the mechanisms controlling stability and intracellular trafficking of NLRP3 in human macrophages.

Indexed as

InflammasomesMembrane ProteinsNLR Family, Pyrin Domain-Containing 3 Proteinrab GTP-Binding ProteinsAnimalsEndosomesHEK293 CellsHumansI-kappa B KinaseMacrophagesMAP Kinase Kinase KinasesPhosphorylationProtein StabilityProtein Transportrab11 GTP-Binding ProteinsI-kappa B KinaseInflammasomesMAP Kinase Kinase KinasesMembrane ProteinsNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanRAB11FIP2 protein, humanrab11 GTP-Binding Proteinsrab GTP-Binding ProteinsEarly EndosomeInflammasome ActivationLPS PrimingNLRP3 StabilityRab11-FIP2

Identifiers

PMID41882227
PMCPMC13144346

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.